Ischemic Stroke and Reduced Left Ventricular Ejection Fraction: A Multidisciplinary Approach to Optimize Brain and Cardiac Health.

Reduced left ventricular ejection fraction ≤40%, a known risk factor for adverse cardiac outcomes and recurrent acute ischemic stroke, may be detected during an acute ischemic stroke hospitalization. A multidisciplinary care paradigm informed by neurology and cardiology expertise may facilitate the timely implementation of an array of proven heart failure-specific therapies and procedures in a nuanced manner to optimize brain and cardiac health.
Competing Interests: Disclosures Dr Merkler has received fees for medicolegal consulting. Dr Freeman has received salary support from the American College of Cardiology National Cardiovascular Data Registry and the National Heart, Lung, and Blood Institute; has received consulting/Advisory Board fees (modest) from Boston Scientific, Medtronic, Janssen Pharmaceuticals, and Biosense Webster; and has equity interest in PaceMate. Dr Krumholz is the editor-in-chief of the Journal of the American College of Cardiology; works under contract with the Centers for Medicare and Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect inferior vena cava filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and cofounder of Refactor Health, a healthcare AI-augmented data management company. Dr Ahmad has received consulting fees from Sanofi, Amgen, and Cytokinetics and has received research funding from Boehringer Ingelheim, AstraZeneca, Cytokinetics, and Relypsa. Dr Sharma is a co-inventor of US Provisional Patent Application No. 63/505,006, Methods of Training an Algorithm To Predict Ischemic Stroke Etiology; reports funding from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS; K23NS121634). The other authors report no conflicts.